Larimar Therapeutics (LRMR)

• Market cap: $305M
• 1 day: 5.64%
• 5 days: 5.33%
• 1 month: -17.02%
• 3 months: -3.52%
• 6 months: 84.46%
• Year to date: -11.22%
• 1 year: -41.92%
• 5 years: -81.54%
• 10 years: -98.1%
• Sector: Healthcare
• Industry: Biotechnology

About: Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.

Employees: 65